19 June 2013
Keywords: repligen, begins, ph, ii, secretin, autism, corp
Article | 06 April 2000
Repligen Corp has initiated a Phase II clinical trial of the hormonesecretin, which is US-approved for the diagnosis of gastrinoma ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
18 June 2013
© 2013 thepharmaletter.com